| Literature DB >> 28670076 |
Saadeddine Saad1, Bobbak Mansouri1, Chad Housewright1.
Abstract
Imiquimod activates the immune system when applied to a local area. We report a patient with a history of well-controlled myasthenia gravis who was prescribed imiquimod for lentigo maligna. Treatment was halted after 2 weeks when the patient reported itching and irritating sensations in his throat, consistent with previous myasthenia exacerbations. The symptoms improved once imiquimod use was discontinued. We advise clinicians to be cautious when prescribing imiquimod to a patient with a history of myasthenia gravis.Entities:
Year: 2017 PMID: 28670076 PMCID: PMC5468034 DOI: 10.1080/08998280.2017.11929637
Source DB: PubMed Journal: Proc (Bayl Univ Med Cent) ISSN: 0899-8280